NR4A1 and breast carcinoma: As current evidence does not adequately resolve questions of the use of OFS in hormone receptor positive early breast cancer patients, the present systematic review and meta-analysis was conducted with the aim of assessing the efficacy of OFS in premenopausal hormone receptor positive early breast cancer patients.